Free Trial
Final Hours! Save $100 on MarketBeat All Access Before 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion
Joseph Catanzaro

Joseph Catanzaro Analyst Performance

Executive Director, Senior Biotech Equity Analyst at Mizuho

Joseph Catanzaro is a stock analyst at Mizuho focused in the medical sector, covering 30 publicly traded companies. Over the past year, Joseph Catanzaro has issued 39 stock ratings, including strong buy, buy, and hold recommendations. While full access to Joseph Catanzaro's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Joseph Catanzaro's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
86 Last 7 Years
Buy Recommendations
84.34% 70 Buy Ratings
Companies Covered
30 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy9.6%8 ratings
Buy74.7%62 ratings
Hold15.7%13 ratings
Sell0.0%0 ratings

Out of 83 total stock ratings issued by Joseph Catanzaro at Mizuho, the majority (74.7%) have been Buy recommendations, followed by 15.7% Hold and 9.6% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
96.7% of companies on NASDAQ
29 companies
NYSE
3.3% of companies on NYSE
1 company

Joseph Catanzaro, an analyst at Mizuho, currently covers 30 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
28 companies
93.3%
Manufacturing
1 company
3.3%
Retail/Wholesale
1 company
3.3%

Joseph Catanzaro of Mizuho specializes in stock coverage within the Medical sector, with additional focus on Manufacturing and Retail/Wholesale companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
22 companies
73.3%
MED - DRUGS
3 companies
10.0%
BIOTECHNOLOGY
2 companies
6.7%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
1 company
3.3%
MEDICAL INFO SYS
1 company
3.3%
RETAIL - APP/SHOE
1 company
3.3%

Joseph Catanzaro's Ratings History at Mizuho

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
5/22/2026Initiated Coverage$5.50$14.00Outperform
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
5/22/2026Initiated Coverage$5.80$14.00Outperform
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
5/15/2026Boost Price Target$22.14$30.00Outperform
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
5/14/2026Boost Price Target$19.85$45.00Outperform
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
5/14/2026Lower Price Target$9.36$50.00Outperform
Erasca, Inc. stock logo
ERAS
Erasca
5/12/2026Lower Price Target$10.44$26.00Outperform
Climb Bio, Inc. stock logo
CLYM
Climb Bio
4/15/2026Initiated Coverage$8.85$18.00Outperform
Climb Bio, Inc. stock logo
CLYM
Climb Bio
4/15/2026Initiated Coverage$8.65$18.00Outperform
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
3/30/2026Boost Price Target$78.10$110.00Outperform
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3/23/2026Boost Price Target$4.47$12.00Overweight
Erasca, Inc. stock logo
ERAS
Erasca
3/13/2026Boost Price Target$15.19$19.00Outperform
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
3/11/2026Boost Price Target$16.34$20.00Outperform
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
3/4/2026Reiterated Rating$10.00$12.00Overweight
EIKN
EIKN
3/2/2026Initiated Coverage$13.78$26.00Outperform
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
2/23/2026Initiated Coverage$12.20$19.00Outperform
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
1/29/2026Boost Price Target$17.87$35.00Overweight
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
1/20/2026Boost Price Target$5.52$7.00Overweight
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
1/20/2026Boost Price Target$5.39$10.00Overweight
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
12/18/2025Upgrade$18.91Strong-Buy
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
12/18/2025Upgrade$17.64Hold
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
12/18/2025Upgrade$33.47Strong-Buy
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
12/18/2025Upgrade$29.86Strong-Buy
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
12/17/2025Set Price Target$19.25$39.00Outperform
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
12/17/2025Initiated Coverage$28.33$51.00Outperform
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
12/17/2025Initiated Coverage$17.98$18.00Neutral
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
12/17/2025Initiated Coverage$33.06$53.00Outperform
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
12/11/2025Boost Price Target$89.89$120.00Outperform
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
12/10/2025Boost Price Target$19.87$30.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
10/21/2025Initiated Coverage$54.01$90.00Outperform
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
10/21/2025Initiated Coverage$10.39$24.00Outperform
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
10/21/2025Initiated Coverage$60.50$81.00Outperform
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
10/21/2025Initiated Coverage$27.67$48.00Outperform
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
10/21/2025Initiated Coverage$56.94$105.00Outperform
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
10/20/2025Upgrade$53.48Strong-Buy
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
10/20/2025Upgrade$26.72Strong-Buy
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
10/20/2025Upgrade$55.80Strong-Buy
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
10/20/2025Upgrade$10.63Strong-Buy
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
10/20/2025Upgrade$52.98Strong-Buy
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
10/10/2025Lower Price Target$10.86$32.00Overweight
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
5/20/2025Upgrade$2.80$5.00Overweight
Before you buy SpaceX shares, consider this alternative approach (Ad)

SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.tc pixel

Discover the overlooked SpaceX IPO strategy before the June listing
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
5/15/2025Boost Price Target$1.99$5.00Overweight
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
4/14/2025Initiated Coverage$0.53$2.50Overweight
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
2/28/2025Lower Price Target$5.26$6.00Neutral
Schrodinger, Inc. stock logo
SDGR
Schrodinger
2/27/2025Lower Price Target$21.70$45.00Overweight
Merus N.V. stock logo
MRUS
Merus
2/13/2025Initiated Coverage$40.26$84.00Overweight
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2/12/2025Boost Price Target$103.45$110.00Overweight
Exelixis, Inc. stock logo
EXEL
Exelixis
2/12/2025Boost Price Target$34.91$38.00Overweight
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
1/31/2025Lower Price Target$6.01$7.50Neutral
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
1/17/2025Lower Price Target$11.09$15.00Overweight
Exelixis, Inc. stock logo
EXEL
Exelixis
1/13/2025Boost Price Target$35.09$37.00Overweight
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
1/10/2025Boost Price Target$53.13$53.00Neutral